Suppression of Pneumocystis carinii using aerosolized pentamidine treatment
First Claim
1. A method of treating Pneumonia caused by Pneumocystis carinii in a human patient by providing a pentamidine aerosol having a mean particle diameter from about 0.25 to about 5 μ
- m and administering an Pharmaceutically effective amount of said aerosol to a patient suffering from Pneumocystis carinii pulmonary infection, whereby said aerosol is delivered to said patient'"'"'s alveoli using a nebulizer consisting essentially of;
(a) a tube providing an oxygen flow into the nebulizer;
(b) a nebulizer container holding the pentamidine solution for generation of aerosolized particles in a conduit;
(c) the conduit;
(d) a mouthpiece;
(e) a one way valve having a baffle for reducing larger particle sizes to particles having a mean diameter from about 0.25 to about 5 μ
m; and
(f) a one way valve leading to particle filter for removal of residual pentamidine during exhalation.
1 Assignment
0 Petitions
Accused Products
Abstract
A method of preventing clinically manifest Pneumocystis carinii pneumonia in immunocompromised humans is provided wherein an aerosol of pentamidine is administered to the patient in a manner which delivers the aerosol to the patient'"'"'s alveoli. Also provided is a method of treating Pneumocystis carinii pneumonia in HIV seropositive individuals comprising administering a therapeutically effective amount of pentamidine aerosol to the HIV positive individual through inhalation. In addition, a method is provided of administering pentamidine to a human comprising aerosolizing a pentamidine solution in a nebulizer system having a one-way valve disposed between the nebulizer and the mouthpiece of the nebulizer system.
33 Citations
17 Claims
-
1. A method of treating Pneumonia caused by Pneumocystis carinii in a human patient by providing a pentamidine aerosol having a mean particle diameter from about 0.25 to about 5 μ
- m and administering an Pharmaceutically effective amount of said aerosol to a patient suffering from Pneumocystis carinii pulmonary infection, whereby said aerosol is delivered to said patient'"'"'s alveoli using a nebulizer consisting essentially of;
(a) a tube providing an oxygen flow into the nebulizer; (b) a nebulizer container holding the pentamidine solution for generation of aerosolized particles in a conduit; (c) the conduit; (d) a mouthpiece; (e) a one way valve having a baffle for reducing larger particle sizes to particles having a mean diameter from about 0.25 to about 5 μ
m; and(f) a one way valve leading to particle filter for removal of residual pentamidine during exhalation. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 16, 17)
- m and administering an Pharmaceutically effective amount of said aerosol to a patient suffering from Pneumocystis carinii pulmonary infection, whereby said aerosol is delivered to said patient'"'"'s alveoli using a nebulizer consisting essentially of;
-
14. A method for inhibiting the growth of Pneumocystis carinii in a human being by delivering, by inhalation, to the respiratory system of a patient suffering from Pneumonia causing Pneumocystis carinii, an aerosol suspension of pentamidine, having a mean particle diameter within a range from about 0.25 μ
- m to about 2.5 μ
m using a nebulizer consisting essentially of;(a) a tube providing an oxygen flow into the nebulizer; (b) a nebulizer container holding a pentamidine solution for generation of aerosolized particles in a conduit; (c) the conduit; (d) a mouthpiece; (e) a one way valve having a baffle for reducing larger particle sizes to particles having a mean diameter from about 0.25 to about 5 μ
m; and(f) a one way valve leading to particle filter for removal of residual pentamidine during exhalation; wherein said pentamidine suspension is delivered in an amount sufficient to inhibit the growth of Pneymocystis carinii.
- m to about 2.5 μ
Specification